Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aditya Sarawgi

REVEALED: Do wall street analysts like moderna stock - The Real Truth

Valued at $13.1 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage pharmaceutical company. It focuses on discovering and developing messenger RNA (mRNA) based therapies and vaccines for the treatment of autoimmune conditions, infectious, immuno-oncology, rare, and cardiovascular diseases.

Moderna has significantly underperformed the broader market over the past year. MRNA stock has tanked 63.4% over the past 52 weeks and 15.9% on a YTD basis, compared to the S&P 500 Index’s ($SPX) 22.6% surge over the past year and 3.1% gains in 2025.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.